IP Library Granted Patent US 7,973,169
Granted Patent B2
US 7,973,169 · App. 10/936,448 · Granted Jul 5, 2011

Modulators of ATP-Binding Cassette transporters

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,973,169
App. No.
10/936,448
Granted
Jul 5, 2011
Kind
B2
Abstract

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Claims (39)

1. A compound having formula (II) or formula (III):

or a pharmaceutically acceptable salt thereof;

wherein:

X 1 is a bond, O, S, CF 2 , CH 2 , or NR;

R is H or R 2

A 1 is aryl, or heteroaryl;

each B 1 is independently selected from a 3-7 membered monocyclic, saturated, unsaturated or aryl ring containing 0-4 heteroatoms selected from N, S, or O;

wherein each A 1 or B 1 is optionally substituted with up to 4 substituents independently selected from R1, R2, R3, R4, or R5;

each B 1 is independently selected from 3-7 membered monocyclic, saturated, unsaturated or aromatic ring containing 0-4 heteroatoms selected from N, NH, S, or O;

wherein each A 1 is optionally substituted with up to 4 substituents independently selected from R 1 , R 2 , R 3 , R 4 , or R 5 ;

R 1 is R 6 or ((C1-C4)aliphatic) n -Y;

n is 0 or 1;

Y is halo, CN, CF 3 , OCF 3 , OH, NH 2 , NHR 6 , N(R 6 ) 2 , COOH, COOR 6 or OR 6 ; or

two R 1 on adjacent ring atoms, taken together, form 1,2-methylenedioxy or 1,2-ethylenedioxy;

R 2 is aliphatic, wherein each R 2 is optionally substituted with up to 2 substituents independently selected from R 1 , R 4 , or R 5 ;

R 3 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring optionally substituted with up to 3 substituents, independently selected from R 1 , R 2 , R 4 or R 5 ;

R 4 is OR 5 , C(O)R 5 , C(O)OR 5 , C(O)R 6 , C(O)OR 6 , C(O)N(R 6 ) 2 , C(O)N(R 5 ) 2 , or C(O)N(R 5 R 6 );

R 5 is a cycloaliphatic, aryl, heterocyclic, or heteroaryl ring, optionally substituted with up to 3 R 1 substituents; and

R 6 is H or aliphatic;

provided that for compounds of formula (II):

(i) when both B 1 are simultaneously phenyl and X 1 is CH 2 , then A 1 is not 4-fluoro-phenyl, 4-phenyl-piperidyl, phenyl, 2,4-dichloro-phenyl, 4-methoxy-phenyl, 3,4-dichloro-phenyl, 2,5-dichloro-phenyl, 4-nitro-phenyl, 4-bromo-phenyl, 4-methyl-phenyl, 2-chloro-phenyl, 1-naphthyl, 3-trifluoromethyl-phenyl, 2,3-dichlorophenyl, N-morpholinyl, 4-chloro-phenyl, 3-chloro-phenyl, or 3-nitro-phenyl; and

(ii) when X 1 is a bond, then A 1 is not an optionally substituted 6-membered heteroaryl ring with 1-3 nitrogen ring atoms; and

provided that for compounds of formula (III):

(i) when X 1 is a bond, one B 1 is phenyl and the other B 1 is N-piperidyl, then A 1 is not:

(ii) when X 1 is a bond, then A 1 is not an optionally substituted 6-membered heteroaryl ring with 1-3 nitrogen ring atoms.

2. The compound according to claim 1 , wherein X 1 is CH 2 , CF 2 , or O.

3. The compound according to claim 1 , wherein X 1 is CH 2 .

4. The compound according to claim 1 , wherein A 1 is selected from phenyl, triazinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyridyl, pyrazolyl, quinolinyl, isoquinolinyl, or naphthyl.

5. The compound according to claim 1 , wherein each B 1 is independently an optionally substituted phenyl or naphthyl.

6. The compound according to claim 1 , wherein each B 1 is an unsubstituted phenyl.

7. The compound according to claim 1 , wherein each B 1 is independently selected from optionally substituted C5-C7 heteroaryl.

8. The compound according to claim 7 , wherein each B 1 is independently selected from optionally substituted pyrazolyl or imidazolyl.

9. The compound according to claim 1 , wherein B 1 is selected from optionally substituted pyrrolinyl, pyrazolinyl, piperidinyl, morpholinyl, or piperazinyl.

10. The compound according to claim 1 , wherein A 1 is optionally substituted C6-C 10 aryl ring.

11. The compound according to claim 10 , wherein A 1 is optionally substituted phenyl or naphthyl.

12. The compound according to claim 1 , wherein A 1 is optionally substituted C5-C12 heteroaryl ring.

13. The compound according to claim 12 , wherein A 1 is pyridinyl.

14. The compound according to claim 1 , wherein each B 1 is independently an optionally substituted 3-7 membered heterocyclic ring having up to 4 heteroatoms selected from O, S, or N.

15. The compound according to claim 14 , wherein each B 1 is independently selected from optionally substituted pyrrolidyl, pyrrolidinyl, pyranyl, piperidinyl, or morpholinyl.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 21, 2005
From: HADIDA RUAH, SARA S.; MILLER, MARK T.; SINGH, ASHVANI K.; CLEVELAND, THOMAS; MAKINGS, LEWIS R.; HAMILTON, MATTHEW; GROOTENHUIS, PETER D.J.
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 016478/0516 →
Continuity (2)
Provisional Application 60500444 · Sep 6, 2003
Related Publication 20050176789A1 · Aug 11, 2005